| On October 31, 2025, the Centers for Medicare & Medicaid Services (CMS) issued the Final Rule for the Calendar Year 2026 Physician Fee Schedule (PFS), which includes key provisions on how drug manufacturers calculate Average Sales Price (ASP). The Final Rule becomes effective January 1, 2026.
Most notably, CMS finalized new provisions to tighten how drug manufacturers classify BFSFs for calculating the Average Sales Price (ASP). These revisions impose additional administrative responsibilities, including expanded documentation requirements and formal certification procedures. Most notably, Fair Market Value documentation.
CMS is requiring manufacturers to submit documentation of the methodology used to determine whether the fees the manufacturer treats as BFSFs for the ASP calculation are consistent with FMV. CMS stated that the requirement should not “impose an undue burden on manufacturers” because “manufacturers should already maintain sufficient internal documentation to support their FMV assessments.” CMS clarified that all FMV determinations for current contracts will be due by April 30, 2026. CMS also stated that “to reduce administrative burden, CMS will accept well-detailed summaries of FMV methodologies that clearly describe the data sources, assumptions, and rationale supporting the documentation.”
Contact HVG for assistance with proper, supportable documentation for the FMV of BFSF. |